- Home
- BNC vs NGEN Comparison
BNC vs NGEN Comparison
Compare BNC & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNC | NGEN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 314.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BNC | NGEN |
|---|---|---|
| Price | $3.21 | $3.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 233.6K | 166.1K |
| Earning Date | 07-24-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.39 | $3.51 |
| 52 Week High | $31.62 | $5.93 |
Technical Indicators
Market Signals| Indicator | BNC | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 44.16 |
| Support Level | $2.93 | $3.65 |
| Resistance Level | $4.14 | $4.44 |
| Average True Range (ATR) | 0.21 | 0.21 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 73.75 | 34.48 |
Price Performance
Historical ComparisonAbout BNC CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.